Andrew J. Roth

Articles

Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment

October 6th 2016

William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

TNBC Subgroup Stands to Benefit From Androgen Receptor Antagonists

October 3rd 2016

Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.

Treatment Paradigm for TNBC Continues to Evolve

October 3rd 2016

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

September 12th 2016

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC

September 11th 2016

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Regorafenib Poised as Second-Line Standard of Care in HCC

September 10th 2016

Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.

Midostaurin Shows Promise in Advanced Mastocytosis Trial

August 27th 2016

The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.

FDA Approves Dronabinol Solution to Treat CINV

August 3rd 2016

A dronabinol oral solution (Syndros) has been approved by the FDA as a treatment for patients with chemotherapy-induced nausea and vomiting (CINV) in those who have not responded to conventional antiemetic therapies.

Early Integration of Palliative Care Improves Outcomes for Family Caregivers

May 19th 2016

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

Proactive, Team-Based Approach Leads to Better Care, Fewer Treatment Delays for Head and Neck Cancer Patients

April 28th 2016

A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.